UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007882 |
|---|---|
| Receipt number | R000009285 |
| Scientific Title | Multicenter double-blind randomized comparative parallel study with concomitant therapy of 3 drugs, aprepitant + dexamethasone+palonosetron or aprepitant + dexamethasone+ granisetron, for prevention of nausea/vomiting in breast cancer patients receiving AC therapy |
| Date of disclosure of the study information | 2012/05/02 |
| Last modified on | 2016/06/07 12:35:28 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Multicenter double-blind randomized comparative parallel study with concomitant therapy of 3 drugs, aprepitant + dexamethasone+palonosetron or aprepitant + dexamethasone+ granisetron, for prevention of nausea/vomiting in breast cancer patients receiving AC therapy
Acronym
Comparison of concomitant therapy with 3 drugs, aprepitant + dexamethasone+5HT3ra (palonosetron or granisetron), for prevention of nausea/vomiting in breast cancer patients receiving AC therapy;Trial for Antiemetic Triplet Therapy(TTT)
Scientific Title
Multicenter double-blind randomized comparative parallel study with concomitant therapy of 3 drugs, aprepitant + dexamethasone+palonosetron or aprepitant + dexamethasone+ granisetron, for prevention of nausea/vomiting in breast cancer patients receiving AC therapy
Scientific Title:Acronym
Comparison of concomitant therapy with 3 drugs, aprepitant + dexamethasone+5HT3ra (palonosetron or granisetron), for prevention of nausea/vomiting in breast cancer patients receiving AC therapy;Trial for Antiemetic Triplet Therapy(TTT)
Region
| Japan |
Condition
Condition
Breast Cancer
Classification by specialty
| Breast surgery | Adult |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To examine the efficacy of new antiemetic drugs (palonosetron) in AC therapy for breast cancer patients
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Phase III
Assessment
Primary outcomes
The proportion of patients who showed complete response (no vomiting and no salvage treatment) during a period from 24 to 120 hours after AC therapy
Key secondary outcomes
(1)The proportion of patients who showed complete response (no vomiting and no salvage treatment) from 0 to 24 hours of AC therapy
(2)The proportion of patients who showed complete response (no vomiting and no salvage treatment) from 0 to 120 hours of AC therapy
(3)proportion of patients who showed no nausea / degree of nausea
(4)QOL
(5)Dietary intake
(6)Adverse events
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Active
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is considered as adjustment factor in dynamic allocation.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Aprepitant (day 1: 125 mg, days 2-3:80mg) + dexamethasone (day 1: 9.9 mg) + granisetron (day 1: 40(microgram)/kg)
Interventions/Control_2
Aprepitant (day 1: 125 mg, days 2-3:80mg) + dexamethasone (day 1: 9.9 mg) + palonosetron (day 1: 0.75 mg)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Female
Key inclusion criteria
1) Patients aged >= 20 years old and <= 75 years old (at the time informed consent was obtained)
2) Female patients
3) Patients with primary breast cancer of stages I to III who are scheduled to receive AC therapy
4) Patients with an ECOG Performance Status of 0 - 1
5) Patients who can correctly fill in a symptom diary
6) Patients who meet the following standard values in general clinical tests:
-White blood cells >= 3,000 /mm**3, and neutrophils >= 1,500 /mm**3
-Blood platelet count>= 100,000 /mm**3 -AST (GOT) and ALT (GPT) <= 2.5 times the high end of the normal range at the facility
-Total bilirubin <= 1.5 times the high end of the normal range at the facility
-Creatinine <= 1.5 times the high end of the normal range at the facility
7) Patients with normal cardiac function:
-ECG within the normal range, no symptoms, and no abnormality requiring treatment
- Cardiac function has been determinined to be normal by Interview, Echocardiography,Chest X-ray, BNP etc
Key exclusion criteria
1) Patients with a history of administration of moderate to high emetogenic chemotherapy
2) Patients receiving administration of an antiemetic drug (5-HT3 receptor antagonist, phenothiazine, butyrophenone, benzamide, or dopamine receptor antagonist)
3) Patients who received administration of a benzodiazepine or narcotic formulation within 48 hours before commencement of AC therapy
4) Patients who received systemic corticosteroid therapy within 72 hours before commencement of AC therapy
5) Patients with a history of gastrointestinal tract surgery (excluding appendectomy)
6) Patients who received or are scheduled to receive radiation therapy for the abdominal region (diaphragm or lower) or pelvis for a period from 6 days before commencement of AC therapy until Day 6 of AC therapy
7) Patients who had vomiting or dry vomiting within 24 hours before commencement of AC therapy
8) Patients with active multiple cancer (synchronous multiple cancer or metachronous multiple cancer with a disease-free interval of 5 years or less)
9) Patients with a symptomatic cerebral tumor (including a benign tumor)
10) Patients who received administration of the following drugs within 7 days before commencement of AC therapy: clarithromycin, erythromycin, ketoconazole, itraconazole, and digoxin
11) Patients who received administration of the following drugs within 4 weeks before commencement of AC therapy: barbiturate drug, rifampicin, phenytoin, and carbamazepine
12) Pregnant or lactating patients, patients who may be pregnant, patients hoping to become pregnant during the study period, and patients taking an oral contraceptive
13) Patients who have coexisting diseases, such as systemic infection, hepatitis, and uncontrollable diabetes, in whom dexamethasone sodium phosphate cannot be administered
14) Patients with a history of hypersensitivity to granisetron, palonosetron, aprepitant or dexamethasone
15) Other patients who are judged to be inappropriate for the study by the investigator.
Target sample size
660
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Mitsue Saito |
Organization
Juntendo University Hospital
Division name
Department of Breast Oncology
Zip code
Address
3-1-3, Hongo, Bunkyo-ku, Tokyo 113-8421
TEL
03-3813-3111
mitsue@juntendo.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Mitsue Saito |
Organization
Juntendo University Hospital
Division name
Department of Breast Oncology
Zip code
Address
3-1-3, Hongo, Bunkyo-ku, Tokyo 113-8421
TEL
03-3813-3111
Homepage URL
mitsue@juntendo.ac.jp
Sponsor or person
Institute
Juntendo Clinical Research Support Center
Institute
Department
Personal name
Funding Source
Organization
Non-Profit Organization: Japan Clinical Research Support Unit
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Juntendo Nerima Hospital,Juntendo Urayasu Hospital,Juntendo Shizuoka Hospital,Shizuoka General Hospital,Mie University Hospital,Sapporo Medical University Hospital,Toho University Omori Medical Center,Ome Municipal General Hospital,Nippon Medical School Musashi Kosugi Hospital,Tottori University Hospital,Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Tokyo Medical University Hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
順天堂大学医学部附属順天堂医院（東京）,順天堂大学附属練馬病院（東京）,順天堂大学附属浦安病院（千葉）,順天堂大学附属静岡病院（静岡）,静岡県立総合病院（静岡）,三重大学医学部附属病院（三重）,札幌医科大学附属病院（北海道）,東邦大学医療センター大森病院（東京）,青梅市立総合病院（東京）,日本医科大学武蔵小杉病院（神奈川）,鳥取大学医学部附属病院（鳥取）,関東中央病院（東京）,東京医科大学病院（東京）
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 05 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2011 | Year | 08 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 10 | Month | 31 | Day |
Date of closure to data entry
| 2015 | Year | 12 | Month | 01 | Day |
Date trial data considered complete
| 2015 | Year | 12 | Month | 24 | Day |
Date analysis concluded
| 2016 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2012 | Year | 05 | Month | 02 | Day |
Last modified on
| 2016 | Year | 06 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009285
